ArticleNPJ breast cancer2024

Palbociclib and letrozole for hormone receptor-positive HER2-negative breast cancer with residual disease after neoadjuvant chemotherapy.

Sonia Pernas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.